| Identification | Back Directory | [Name]
1H-Imidazo[4,5-c]quinolin-4-amine, 1-[[3-(aminomethyl)phenyl]methyl]-2-butyl- | [CAS]
1258457-58-7 | [Synonyms]
1-(3-(Aminomethyl)benzyl)-2-butyl-1H-imidazo[4,5-c]quinolin-4-amine 1H-Imidazo[4,5-c]quinolin-4-amine, 1-[[3-(aminomethyl)phenyl]methyl]-2-butyl- | [Molecular Formula]
C22H25N5 | [MOL File]
1258457-58-7.mol | [Molecular Weight]
359.47 |
| Hazard Information | Back Directory | [Uses]
m-AM-BBIQ (compound 10) is a dual TLR7 and TLR8 agonist, with EC50 values of 0.12 μM and 1.7 μM for hTLR7 and hTLR8, respectively[1]. | [References]
[1] Kushvinder Kumar, et al. Modulation of the Adjuvant Potential of Imidazoquinoline-Based TLR7/8 Agonists via Alum Adsorption. ACS Med. Chem. Lett. 2024, July. 22. |
|
| Company Name: |
Biorbyt Ltd.
|
| Tel: |
+44 (0)1223 859 353 |
| Website: |
http://www.biorbyt.com |
|